CCXI Insider Trading Activity and SEC Form 4 Filings
CCXI insider trading summary
No open-market insider purchases or sales of ChemoCentryx, Inc. (CCXI) have been reported on SEC Form 4 in the past 12 months.
Latest CCXI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 16, 2022 | Susan M Kanaya | EVP, CFO and Sec. | Sell | $1.0M (19,898 @ $50.95) |
| Aug 4, 2022 | James L Tyree | Director | Sell | $502K (10,000 @ $50.22) |
| Aug 4, 2022 | Susan M Kanaya | EVP, CFO and Sec. | Sell | $2.3M (46,298 @ $50.17) |
| Aug 4, 2022 | Markus J. Cappel | Chief Bus. Officer & Treasurer | Sell | $380K (7,564 @ $50.22) |
| Aug 4, 2022 | Thomas J. Schall | President and CEO | Sell | $6.5M (130,000 @ $50.24) |
| Jun 9, 2022 | James L Tyree | Director | Sell | $2K (59 @ $26.22) |
| Jun 9, 2022 | James L Tyree | Director | Sell | $98K (3,804 @ $25.65) |
| Dec 17, 2021 | James L Tyree | Director | Sell | $94K (2,800 @ $33.52) |
| Dec 17, 2021 | James L Tyree | Director | Sell | $578K (16,634 @ $34.74) |
| Dec 17, 2021 | James L Tyree | Director | Sell | $641K (18,066 @ $35.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.